Votrient (Pazopanib) 200mg*30 | Novartis China | GLT

Generic Information: Votrient (Pazopanib) 200mg — China-Mainland

This is the China-Mainland presentation of Votrient, the originator pazopanib. Pazopanib was originally developed by GlaxoSmithKline and transferred to Novartis, which now markets it worldwide under the brand name Votrient (Chinese brand "维全特/培唑帕尼"). This listing is the 200 mg film-coated tablet in a 30-tablet pack, supplied by Novartis's Swiss manufacturing entity for the Chinese market.

Pazopanib is approved in China for advanced renal cell carcinoma in the first-line setting and after prior cytokine therapy. It has been included in China's national medical insurance scheme for the RCC indication, which makes the China presentation of the originator meaningfully more affordable than Western list prices. Buyers should note that the China pack is a 30-tablet box rather than the larger Western presentations.

What Is Votrient Used For?

Votrient treats advanced renal cell carcinoma (RCC) as a first-line therapy and in patients who have received prior cytokine treatment. It is also used for advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy. Both indications rely on pazopanib's anti-angiogenic mechanism to slow tumour progression.

How Does Votrient Work?

Pazopanib is a multi-targeted tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-α, -β) and c-Kit. By inhibiting these kinases, Votrient disrupts angiogenesis — the growth of new blood vessels that tumours depend on — reducing blood supply to the tumour and slowing its growth.

Indications

• Advanced renal cell carcinoma (RCC), first-line and after prior cytokine therapy.
• Advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy.

Dosage and Administration

The recommended dose is 800 mg once daily, taken as four 200 mg tablets, at least 1 hour before or 2 hours after a meal, swallowed whole. A 30-tablet box provides just over a week of therapy at the standard dose, so patients typically receive multiple boxes per month. Dose adjustment is required for hepatic impairment, and liver function and blood pressure are monitored throughout treatment.

Side Effects

Common adverse reactions include diarrhoea, hypertension, hair colour changes, nausea, fatigue, decreased appetite and vomiting. Votrient carries a boxed warning for severe hepatotoxicity, requiring liver function monitoring before and during therapy. Hypothyroidism, haemorrhage and QT prolongation may also occur, and patients should report yellowing of the skin, unusual bleeding or palpitations.

Storage

Store below 30°C in the original package, away from moisture and out of the reach of children. Use before the expiry date printed on the pack.

Why Choose the China Version of Votrient?

The China-Mainland Votrient is priced substantially below the US list price of the same medicine — roughly a fraction of Western pricing — because it is nationally reimbursed in China for the RCC indication. This makes the China presentation one of the more economical ways to access originator pazopanib. GLT documents each batch and guides international buyers through the export and import requirements for sourcing the China version.

How to Order Votrient (China) from GLT

To order the China-Mainland Votrient 200 mg (30 tablets), message GLT on WhatsApp at +86 15234153837 or email [email protected]. State your quantity, destination and order type, and we confirm the current China price, batch origin and required documentation before dispatch.

FAQ

Who makes Votrient? Votrient (pazopanib) was developed by GlaxoSmithKline and is now marketed by Novartis worldwide.

Is Votrient reimbursed in China? Yes, pazopanib is included in China's national medical insurance scheme for the advanced renal cell carcinoma indication.

What strength is available? This listing is the 200 mg tablet in a 30-tablet pack; the 400 mg strength is also available in some markets.